Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.
Department of Medical Laboratory Sciences, Faculty of Applied Health Sciences, The Hashemite University, P.O. Box 330127, Zarqa 13133, Jordan.
Life Sci. 2021 Dec 1;286:120063. doi: 10.1016/j.lfs.2021.120063. Epub 2021 Oct 19.
COVID-19 is a multi-faceted disease ranging from asymptomatic to severely ill condition that primarily affects the lungs and could advance to other organs as well. It's causing factor, SARS-CoV-2 is recognized to develop robust cell-mediated immunity that responsible to either control or exaggerate the infection. As an important cell subset that control immune responses and are significantly dysregulated in COVID-19, Tregs is proposed to be considered for COVID-19 management. Among its hallmark, TNFR2 is recently recognized to play important role in the function and survival of Tregs. This review gathers available TNFR2 agonists to directly target Tregs as a potential approach to overcome immune dysregulation that affect the severity in COVID-19. Furthermore, this review performs a rigid body docking of TNF-TNFR2 interaction and such interaction with TNFR2 agonist to predict the optimal targeting approach.
COVID-19 是一种多方面的疾病,从无症状到重病,主要影响肺部,并可能进一步影响其他器官。其致病因子 SARS-CoV-2 被认为会产生强大的细胞介导免疫,从而控制或加剧感染。调节性 T 细胞(Tregs)作为控制免疫反应的重要细胞亚群,在 COVID-19 中显著失调,因此被提议用于 COVID-19 的管理。Tregs 的一个重要特征是,最近发现 TNFR2 在其功能和存活中发挥重要作用。本综述收集了现有的 TNFR2 激动剂,以直接靶向 Tregs,作为克服影响 COVID-19 严重程度的免疫失调的潜在方法。此外,本综述还对 TNF-TNFR2 相互作用及其与 TNFR2 激动剂的相互作用进行了刚体对接,以预测最佳的靶向方法。